Optimal frequency of visits for patients with Systemic Lupus Erythematosus to measure Disease Activity over time

Journal of Rheumatology

Volumn 38, Issue 1, 2011, Pages 60-63

  Ibañez, Dominique ^a   Gladman, Dafna D ^a   Touma, Zahi ^a   Nikpour, Mandana ^b   Urowitz, Murray B ^a  

^a TORONTO WESTERN HOSPITAL   (Canada)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Adjusted mean sledai; Disease activity; Longitudinal study; Systemic lupus erythematosus

Indexed keywords

ADULT; ARTICLE; CLINICAL ASSESSMENT TOOL; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE SEVERITY; FEMALE; HEALTH SERVICE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT ASSESSMENT; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; DISEASE PROGRESSION; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; OFFICE VISITS; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 78650885005     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.100575     Document Type: Article

References (13)

1. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH, and The Committee on Prognosis Studies in SLE. The development and validation of the SLE Disease Activity Index (SLEDAI). Arthritis Rheum 1992;35:630-40.
2. Gladman DD, Ibanez D, Urowitz MB. SLE Disease Activity Index 2000. J Rheumatol 2002;29:288-91.
3. Symmons DP, Coppock JS, Bacon PA, Bresnihan B, Isenberg DA, Maddison P, et al. Development and assessment of a computerized index of clinical disease activity in systemic lupus erythematosus. Members of the British Isles Lupus Assessment Group (BILAG). Q J Med 1988;69:927-37.
4. Isenberg DA, Rahman A, Allen E, Farewell V, Akil M, Bruce IN, et al. BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus. Rheumatology 2005;44:902-6.
5. Liang MH, Socher SA, Larson MG, Schur PH. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 1989;32:1107-18.
6. Bae SC, Koh HK, Chang DK, Kim MH, Park JK, Kim SY. Reliability and validity of systemic lupus activity measure-revised (SLAM-R) for measuring clinical disease activity in systemic lupus erythematosus. Lupus 2001;10:405-9.
7. Gladman DD, Goldsmith CH, Urowitz MB, Bacon P, Bombardier C, Chang CH, et al. Cross-cultural validation of three disease activity indices in systemic lupus erythematosus (SLE). J Rheumatol 1992;19:608-11.
8. Hawker G, Gabriel S, Bombardier C, Goldsmith C, Caron D, Gladman DD. A reliability study of SLEDAI: A disease activity index for systemic lupus erythematosus (SLE). J Rheumatol 1993;20:657-60. (Pubitemid 23138854)
9. Gladman DD, Goldsmith CH, Urowitz MB, Bacon P, Bombardier C, Isenberg DA, et al. Sensitivity to change of 3 systemic lupus erythematosus disease activity indices: international validation. J Rheumatol 1994;21:1468-71.
10. Touma Z, Urowitz MB, Gladman DD. SLEDAI-2K for a 30-day window. Lupus 2010;19:49-51.
11. Ibanez D, Urowitz MB, Gladman DD. Summarizing disease features over time: I. Adjusted mean SLEDAI derivation and application to an index of disease activity in lupus. J Rheumatol 2003;30:1977-82.
12. Ibanez D, Urowitz MB, Gladman DD. Disease activity over time (adjusted mean SLEDAI) predicts mortality and damage in SLE. J Rheumatol 2005;32:824-7.
13. Gladman DD, Urowitz MB, Esdaile JM, Hahn BH, Klippel J, Lahita R, et al. American College of Rheumatology Ad Hoc Committee on SLE Guidelines. Guidelines for referral and management of systemic lupus erythematosus in adults. Arthritis Rheum 1999;42:1785-96.